- Home
- GOVX vs PRTG Comparison
GOVX vs PRTG Comparison
Compare GOVX & PRTG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- PRTG
- Stock Information
- Founded
- GOVX 2001
- PRTG 1973
- Country
- GOVX United States
- PRTG British Virgin Islands
- Employees
- GOVX N/A
- PRTG N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- PRTG Oil & Gas Production
- Sector
- GOVX Health Care
- PRTG Energy
- Exchange
- GOVX Nasdaq
- PRTG Nasdaq
- Market Cap
- GOVX 15.5M
- PRTG 17.7M
- IPO Year
- GOVX N/A
- PRTG N/A
- Fundamental
- Price
- GOVX $0.48
- PRTG $5.84
- Analyst Decision
- GOVX Strong Buy
- PRTG
- Analyst Count
- GOVX 5
- PRTG 0
- Target Price
- GOVX $12.40
- PRTG N/A
- AVG Volume (30 Days)
- GOVX 2.5M
- PRTG 237.7K
- Earning Date
- GOVX 08-05-2025
- PRTG 08-26-2025
- Dividend Yield
- GOVX N/A
- PRTG N/A
- EPS Growth
- GOVX N/A
- PRTG N/A
- EPS
- GOVX N/A
- PRTG N/A
- Revenue
- GOVX $5,591,576.00
- PRTG N/A
- Revenue This Year
- GOVX N/A
- PRTG N/A
- Revenue Next Year
- GOVX N/A
- PRTG N/A
- P/E Ratio
- GOVX N/A
- PRTG N/A
- Revenue Growth
- GOVX N/A
- PRTG N/A
- 52 Week Low
- GOVX $0.43
- PRTG $2.10
- 52 Week High
- GOVX $11.18
- PRTG $23.01
- Technical
- Relative Strength Index (RSI)
- GOVX 28.87
- PRTG 41.03
- Support Level
- GOVX $0.43
- PRTG $5.32
- Resistance Level
- GOVX $0.98
- PRTG $6.00
- Average True Range (ATR)
- GOVX 0.15
- PRTG 0.63
- MACD
- GOVX -0.06
- PRTG 0.02
- Stochastic Oscillator
- GOVX 4.87
- PRTG 29.58
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About PRTG Portage Biotech Inc.
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.